Related references
Note: Only part of the references are listed.Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model
Patricia Alamo et al.
FASEB JOURNAL (2015)
A Multicenter Blinded Study Evaluating EGFR and KRAS Mutation Testing Methods in the Clinical Non-Small Cell Lung Cancer Setting-IFCT/ERMETIC2 Project Part 1 Comparison of Testing Methods in 20 French Molecular Genetic National Cancer Institute Platforms
Michele Beau-Faller et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2014)
The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma
Benjamin Izar et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma
Ernest Nadal et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Hypoxia differentially regulated CXCR4 and CXCR7 signaling in colon cancer
Benoit Romain et al.
MOLECULAR CANCER (2014)
Prognostic Value of Epidermal Growth Factor Receptor Mutations in Resected Non-Small Cell Lung Cancer: A Systematic Review with Meta-Analysis
Zhixuan Zhang et al.
PLOS ONE (2014)
Gefitinib Versus Placebo in Completely Resected Non-Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study
Glenwood D. Goss et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: A systematic review with meta-analysis
Daquan Meng et al.
LUNG CANCER (2013)
Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
Nathan T. Ihle et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib
Sandra P. D'Angelo et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer
M. C. Garassino et al.
ANNALS OF ONCOLOGY (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations
Yelena Y. Janjigian et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping
M. Beau-Faller et al.
BRITISH JOURNAL OF CANCER (2009)
A Gene Expression Signature Associated with K-Ras Addiction Reveals Regulators of EMT and Tumor Cell Survival
Anurag Singh et al.
CANCER CELL (2009)
Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma
Jenifer L. Marks et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Surgical practice in non-primitive cancer treatment in small lung cells. Recommendations of the SFCTCV: surgical practice in lung cancer treatment
P. Thomas et al.
REVUE DES MALADIES RESPIRATOIRES (2008)
Survival of cancer patients in France:: A population-based study from the Association of the French Cancer Registries (FRANCIM)
N. Bossard et al.
EUROPEAN JOURNAL OF CANCER (2007)
Share Paper
